Ποια είναι η τιμή για MetaVia Inc. (MTVA)

Η τιμή για MetaVia Inc. (MTVA) είναι $1.51

Ποια είναι η κεφαλαιοποίηση αγοράς για MetaVia Inc. (MTVA)

Η κεφαλαιοποίηση αγοράς για MetaVia Inc. (MTVA) είναι $3.32M

MetaVia Inc. (MTVA) Ιστορικό Τιμών

Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.

Έτος	Απόδοση
2026 (TTM)	-43.25%
2025	-62.61%
2024	0.00%

Έτος

Απόδοση

2026 (TTM)

-43.25%

2025

-62.61%

2024

0.00%

Εταιρεία	Τιμή μετοχής	Μεταβολή 1Έτ%	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	$505.24	28.63%	US
Argenx SE ARGX.US	$846.09	29.41%	NL
Lonza Group AG LONN.SW	$731.69	6.47%	CH
Samsung Biologics Co.,Ltd. 207940.KS	$1.07K	-6.40%	KR
UCB S.A. UCB.BR	$251.82	11.75%	BE

Εταιρεία

Τιμή μετοχής

Μεταβολή 1Έτ%

Χώρα